For the year ending 2025-12-31, AWHL had -$14K decrease in cash & cash equivalents over the period. -$7,045K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -12,780 |
| Non-cash lease expense | 169 |
| Depreciation and amortization | 112 |
| Stock-based compensation expense | 531 |
| Change in fair value of warrant liabilities | 5,607 |
| Change in fair value of march 2025 convertible notes | -170 |
| Loss upon issuance of march 2025 convertible notes carried at fair value | 1,198 |
| Loss on impairment and disposal of property and equipment | -1 |
| Financing expense for entering into 2025 lincoln park equity line of credit | 412 |
| Accounts receivable | 217 |
| Prepaid expenses and other assets | -242 |
| Inventories | -68 |
| Accounts payable | -936 |
| Accrued liabilities | -1,148 |
| Other liabilities | -118 |
| Net cash used in operating activities | -7,029 |
| Purchase of property and equipment | 16 |
| Purchase of intangible assets | 385 |
| Net cash used in investing activities | -401 |
| Principal repayment of decd loan | 233 |
| Proceeds from issuance of common stock-Two Thousand Twenty Four At The Market Offering Agreement | 3,484 |
| Payment of stock issuance costs-Two Thousand Twenty Four At The Market Offering Agreement | 147 |
| Proceeds from issuance of common stock-Two Thousand Twenty Five Private Placement Offering | 2,949 |
| Payment of stock issuance costs-Two Thousand Twenty Five Private Placement Offering | 140 |
| Proceeds from issuance of common stock from exercise of warrants | 112 |
| Proceeds from march 2025 convertible notes | 1,366 |
| Proceeds from issuance of common stock-Equity Line Of Credit Agreement | 25 |
| Net cash provided by financing activities | 7,416 |
| Net decrease in cash and cash equivalents | -14 |
| Cash and cash equivalents , beginning of year | 1,769 |
| Cash and cash equivalents , end of year | 1,755 |
Aspira Women's Health Inc. (AWHL)
Aspira Women's Health Inc. (AWHL)